Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 29933437.
- Also identified by DOI 10.1093/cid/ciy228 and PMC identifier 6093998.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.
Medical subject headings
- Drug Resistance, Viral
- HIV Infections
- HIV Integrase Inhibitors
- HIV-1
- Heterocyclic Compounds, 3-Ring
- Integrases